Background
==========

Head and neck cancer (HNC) is the 8^th^ most common malignancy worldwide. Despite advances in therapeutic options over the last few decades, treatment toxicities and overall clinical outcomes have remained disappointing, underscoring a need to develop novel therapeutic approaches, particularly those that enhance tumor cell death, while minimizing damage to the surrounding normal tissues.

Materials and methods
=====================

An RNA interference (RNAi)-based high-throughput screen (HTS) was performed for the large-scale identification of novel genes that will selectively sensitize HNC cells to ionizing radiation. The Dharmacon Protein Kinase and Druggable Genome siRNA Libraries were screened using FaDu cells (human hypopharyngeal squamous cell cancer). Radiosensitizing targets were subjected to *in vitro* and *in vivo* characterizations.

Results
=======

Sixty-seven target sequences with potential radiosensitizing effects were identified. Targets reducing the surviving fraction by \>50% at 2 Gy relative to their un-irradiated counterparts were selected for further evaluation. A key regulator of heme biosynthesis, uroporphyrinogen decarboxylase (UROD), was thereby identified as a novel tumor-selective radiosensitizing target, demonstrating both *in vitro* and *in vivo* efficacy. Radiosensitization appeared to be mediated *via* enhancement of tumor oxidative stress from perturbation of iron homeostasis and increased free radical production. UROD was significantly over-expressed in HNC patient biopsies, wherein lower pre-radiation mRNA levels correlated with improved survival, suggesting UROD could potentially predict radiation response. UROD down-regulation also radiosensitized several different human cancer models, while sparing normal cells.

Conclusions
===========

An RNAi-based radiosensitizer HTS has revealed UROD as a potent tumor-selective sensitizer for radiation, with potential relevance to many human malignancies.
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